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MicroRNAs (miRNAs) constitute a family of small non-coding RNA molecules 22–25 nucleotides in length. miRNAs control the 
expression of target genes at the post-transcriptional level by inhibiting translation or by degrading target mRNA through binding 
to complementary sequences in the 3′-untranslated regions. Recent studies have demonstrated that miRNAs are intimately in-
volved in processes leading to nasopharyngeal carcinoma, such as the Epstein-Barr virus-encoded latent membrane protein 1 ac-
tivated signal transduction pathways, gene-regulatory networks, mitosis, tumor angiogenesis, invasion and migration. Exploring 
the relationship between miRNAs and the development of nasopharyngeal carcinoma, will further the understanding of this cancer 
and provide new avenues for diagnosis and treatment. 
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tosis, invasion, migration 
 




MicroRNAs (miRNAs) have been intensively studied in recent 
years. Although consisting of only 22–25 nucleotides, miRNAs 
exert crucial biological functions. miRNA expression varies in 
different kinds of tumor tissues and they have been shown to 
be involved in the initiation and progression of tumors [1]. 
Nasopharyngeal carcinoma (NPC) is a head and neck 
epithelial malignancy that occurs frequently in Southern 
China [2]. It is characterized by high invasiveness and me-
tastasis, and involves Epstein-Barr virus (EBV) infection 
and numerous genetic factors [3]. In this review, we focus 
on recent studies [4] that have described miRNA involve-
ment in the carcinogenesis of NPC. 
1  miRNA biogenesis, regulatory mechanisms 
and biological functions 
1.1  miRNA biogenesis and regulatory mechanisms 
miRNAs are small non-coding RNA molecules of about  
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22–25 nucleotides in length. miRNA genes are first tran-
scribed by RNA polymerase II, to produce molecules hun-
dreds of nucleotides in length, called pri-miRNAs. Then, 
Drosha, an RNA polymerase III, processes pri-miRNAs into 
stem-loop structures, 60–70 nucleotides in length, called 
pre-miRNAs. The transportation protein, Exportin-5, identi-
fies and combines with the 3′-end of pre-miRNAs and, in a 
Ran-GTP-dependent manner, pre-miRNAs are exported 
from the nucleus into cytoplasm. With the involvement of 
another RNase III Dicer, the pre-miRNAs are further 
cleaved into double stranded RNAs (dsRNAs). A helicase 
then degrades one strand of the dsRNA, leaving the other 
strand a mature active miRNA to enter the nucleus and form 
the miRNA-associated RNA-induced silencing complex 
(miRISC) [5–7]. Within this complex, miRNAs can play 
essential roles in biological functions. 
miRNAs control the expression of target genes at the 
post-transcriptional level by inhibiting protein translation or 
by degrading cognate target mRNAs through binding to 
their 3′-untranslated regions (UTRs) with varying degrees 
of sequence complementarity. miRNAs are also involved in 
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post-transcriptional regulation and multiple biological func-
tions [8,9]. Most plant miRNAs are 100% complementary 
with their target genes and fully degrade their target 
mRNAs; however, miRNAs in animals often have only par-
tial complementarity with target genes, so post-transcrip- 
tional translation is inhibited rather than completely blocked 
[10]. As many miRNAs are not completely complementary 
with target mRNAs, post-transcriptional repression is the 
main mode of regulation [11]. Because one miRNA can 
target various mRNAs and one mRNA can be targeted by 
several miRNAs, this small regulator and target genes con-
stitute a complicated regulation network and adds a new 
layer of complexity to the control of gene expression [12]. 
1.2  Biological functions of miRNA 
The target genes of miRNAs are involved in diverse bio-
logical functions, including the development, differentia-
tion, proliferation, apoptosis, stress response and mainte-
nance of stem cell differentiation potential [13]. miRNAs 
are also highly important in the regulation of many biologi-
cal processes involved in carcinogenesis, such as tumor cell 
proliferation, apoptosis, adhesion and tumor angiogenesis. 
Approximately 50% of miRNAs are located in cancer-  
related genome regions, which have a wide and vital role in 
the genetic level control of carcinogenesis [14]. Many of the 
miRNAs act as oncogenes or tumor suppressors [15,16]. 
miRNAs that have oncogene capability are usually called 
“oncomiRs” and include miR-155, miR-17-92 cluster 
(miR-17-5p, miR-17-3p, miR-18a, miR-19a, miR-20a, 
miR-19a-1, miR-92-1) and miR-21 [17–19]. In contrast, the 
tumor suppressor miRNAs include miR-15a, miR-16-1, 
let-7 family, miR-143, miR-145 and miR-34a [20]. Douglas 
[21] called the miRNAs involved in metastasis “me-
tastamir”; those that promote metastasis include miR-10b, 
miR-21, and those that inhibit metastasis include miR-141, 
miR-200a/b/c, miR-146 and miR-335. 
2  Involvement of miRNA in the molecular bi-
ology of nasopharyngeal carcinoma  
2.1  miRNA and EBV 
The EBV could encode multiple miRNA genes, and it was 
the first virus shown to encode miRNA genes [22]. Ac-
cording to recent data provided by miRBase [23], the 
EBV-encoded miRNAs include ebv-miR-BHRF1-1~3 and 
ebv-miR-BART1~22. They are located at separate loci in 
the virus genome, at BHRF1 and BART [24]. BHRF1 is an 
early gene of virus replication, which is highly expressed 
when the lytic and duplicated level of virus is high. It is 
involved in the regulation of lytic and replication cycles 
[25]. BART is expressed during the latent cycle, and inhibits 
the replication of virus, keeping the duplicate level low 
[26].  
EBV-encoded miRNAs are involved in the regulation of 
the lytic-latent switch of EBV and in the resistance to host 
immune responses [27]. These miRNAs not only target the 
virus’ own genes, but also target the host genes [28]. Xia et al. 
[29] reported that miR-BHRF1-3 targets the host gene, 
CXCL11, the repression of which will protect EBV-infected 
B cells from attack by cytotoxic T cells. Choy et al. [30] 
also demonstrated that miR-BART5 targets the host gene, 
PUMA (p53-upregulated modulator of apoptosis), the 
down-regulation of which will inhibit apoptosis of the virus 
infected host cells.  
Iizasa et al. [31] found that the primary transcripts of 
ebv-miR-BART6 (pri-miR-BART6) are edited in latent 
EBV-infected cells, and that mature miR-BART6 is essen-
tial for various stages of latency in cells. Further study [31] 
showed that miR-BART6-5p RNAs could suppress the ex-
pression of the EBNA2 viral oncogene, which is required for 
the transition from type I and II latency (less responsive to 
the immune system) to type III latency (more active to the 
immune system). Also, Zta and Rta viral proteins are essen-
tial for lytic replication of EBV [32]. These results revealed 
that miR-BART6 plays a critical role in the regulation of 
EBV infection and latency. 
These studies indicate that the EBV-encoded miRNAs 
play a vital role in the development of NPC. They not only 
modulate the virus’ own genes to facilitate virus infection 
and latency, but they also affect host target genes to help the 
virus escape from the host immune responses and inhibit 
apoptosis of host cells. 
2.2  miRNA and EBV-encoded LMP1 
EBV-encoded LMP1 (latent membrane protein 1) is an im-
portant viral oncoprotein in NPC development [33]. LMP1 
is produced during EBV type II and III latency, and controls 
the NF-κB signaling pathway and the growth and apoptosis 
of host cells. Natalie et al. [34] showed that LMP1 activates 
the miR-146a promoter through an NF-κB dependent path-
way and induces the expression of miR-146a in B-lympho- 
cytes. miR-146a also plays a role in the induction or main-
tenance of EBV latency by modulating innate immune re-
sponses to virus-infected host cells [35]. Graziana et al. [36] 
also demonstrated that LMP1 trans-activates miR-155 tran-
scription through activating an NF-κB pathway, which plays 
a critical role in the activation of lymphocytes and in the 
EBV-mediated transformation of B cells. PU.1 is the down-
stream target gene of miR-155, which is highly expressed in 
miR-155-deficient B cells and leads to reduced numbers of 
IgG1-switched B cells [36]. Together, these observations 
indicate that miR-155 has a role in antigen-driven B cell 
maturation. 
Lo et al. [37] reported that there are three EBV-encoded 
miRNAs, miR-BART1-5p, miR-BART16 and miRBART17- 
5p, which can downregulate the expression of LMP1. Zheng 
et al. [38] suggested that LMP1 triggers the NF-κB, AP-1 
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and STAT signaling pathways; moreover, the JAK/STAT, 
PI-PLC-PKC pathways become active by upregulating the 
expression of JAK3 (Janus kinase 3) and enhancing the 
phosphorylation of STAT (signal transducers and activators 
of transcription); the constitutive activation of signaling 
cascades triggered by LMP1 can induce a diverse array of 
biological effects that ultimately lead to cell cycle disrup-
tion, the acceleration of G1/S phase and the arrest of G2/M 
phase; LMP1 can also induce the expression of hTERT 
(human telomerase reverse transcriptase) and promote cell 
immortalization. 
These findings reveal that EBV-encoded miRNAs can 
regulate the expression of LMP1. At the same time, LMP1 
can activate signal transduction pathways that activate the 
expression of miRNAs, which then regulate tumor-related 
target genes, ultimately lead to the development of NPC.  
2.3  miRNA in signal transduction pathways and in 
gene-regulatory networks of NPC 
Recent studies [39] suggest that multiple miRNAs may 
work in concert to regulate related target genes in a com-
mon pathway. Therefore, the study of signal transduction 
pathways rather than individual target genes will provide 
new insight into the biological functions of miRNA. Chen  
et al. [40] recently reported that there are 35 miRNAs 
whose expression levels are significantly changed in NPC 
tissue biopsies (11 miRNAs, including miR-196b, miR-138, 
miR-155, miR-142-3p and miR-18a are upregulated in NPC 
samples; 24 miRNAs, including miR-204, miR-449a, 
miR-34c-3p, miR-143 and miR-145 are downregulated in 
NPC samples). Among the 35 miRNAs, there are four 
miRNAs (miR-142-3p, miR-196b, miR-138 and miR-155) 
whose expression levels are significantly upregulated and 
another four (miR-204, miR-195, miR-187 and miR-143) 
whose expression levels are significantly downregulated. 
There are five specific pathways targeted by downregulated 
miRNAs: (1) regulation of the G1/S transition; (2) 
cross-talk between VEGF (vascular endothelial growth fac-
tor) and angiopoietin-1 [41,42] signaling; (3) G-protein(-) 
mediated regulation of MARK-ERK signaling; (4) TGF 
(transforming growth factor), WNT [43] and cytoskeletal 
remodeling; (5) signaling by interaction of mem-
brane-bound ESR1 (estrogen receptor 1) with G-proteins. 
Among these five pathways, regulation of the G1/S transi-
tion and cross-talk between VEGF and angiopoietin-1 sig-
naling are the two most relevant pathways for NPC targeted 
by miRNAs [40]. 
Further discoveries [40] confirmed that the expression 
levels of six target genes (CCND2, CCND3, CDC25A, 
VEGFA, PLCG1 and AKT) are upregulated in the two most 
significant pathways targeted by downregulated miRNAs. 
In other words, the predicted target genes of downregulated 
miRNAs are upregulated in NPC. The studies [40] de-
scribed above indicate that the signaling pathways targeted 
by downregulated miRNAs are involved in the regulation of 
cell cycle, cell survival, apoptosis, and cytoskeletal remod-
eling. Together, these results suggest that the upregulation 
of a predicted target gene has an inverse correlation with the 
downregulation of a specific miRNA. 
miRNAs together with oncogenes, tumor suppressor 
genes and related target genes form a complex tumorigenic 
network in the carcinogenesis of NPC. Zhang et al. [44] 
showed that miR-141 is upregulated in NPC, and acts as an 
oncogene. The expression level of miR-141 can be down-
regulated by knocking down the oncogene c-MYC and re- 
expressing tumor suppressor gene, SPLUNC1. The down-
regulation of miR-141 can affect cell cycle, cell growth, 
apoptosis, migration and metastasis. Using luciferase re-
porter assays and Western blot analysis, Zhang et al. [44] 
further confirmed that BRD3, UBAP1 and PTEN are poten-
tial targets of miR-141. BRD3 and UBAP1 [45–47] are both 
involved in the development of NPC. BRD3 participates in 
the regulation of the Rb/E2F pathway. PTEN participates in 
the regulation of the AKT signaling pathway and acts as a 
vital tumor suppressor gene in various cancers [48]. Inhibi-
tion of miR-141 expression affects the biological functions 
of various molecules in Rb/E2F, JNK2 and AKT signaling 
pathways [44]. Zhang et al. [44] suggested that miR-141 
and tumor-related genes, c-MYC, SPLUNC1, BRD3, UBAP1 
and PTEN are all involved in a “gene-miRNA” network, 
which ultimately leads to the development of NPC. 
Taken together, these studies indicate that during the de-
velopment of NPC, a series of genetic and epigenetic events 
constitute a complicated network system [49–53]. Both on-
cogenes and tumor suppressor genes can regulate the ex-
pression of miRNAs; meanwhile, the expression of the 
relevant miRNA could further modulate the expression of 
tumor-related target genes. Hence, miRNAs, oncogenes, 
tumor suppressor genes and tumor-related target genes are 
all involved in a complex “gene-miRNA-gene” network 
system, which ultimately contributes to the progression of 
NPC. 
3  Role of miRNA in the cell biology of naso-
pharyngeal carcinoma 
3.1  miRNA and mitosis 
Plk1 is a vital regulator in many stages of mitosis and also 
plays a critical role in the cellular proliferation and progres-
sion of NPC [54]. The abnormal expression of Plk1 corre-
lates with the downregulation of miRNA [55]. Plk1, which 
is a vital regulator in the G2/M transition of mitosis, is es-
sential for cell cycle regulation [56]. Wei et al. [55] found 
that miR-100 can modulate the expression of Plk1 in NPC; 
siPlk1, which is a siRNA targeted to Plk1, could alter cell 
structures and induce aberrant spindle formation; Plk1 de-
pletion can also induce abnormal microtubule formation and 
lead to the condensation of chromatin in cancer cells [57]. 
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Wei et al. [55] further showed that siPlk1 could inhibit the 
expression of Plk1 mRNA and protein; the combination of 
ionizing radiation and siPlk1 effectively reduces the viabil-
ity of C666-1 cells and increases γH2AX levels. Plk1 deple-
tion induces significant G2/M arrest and apoptosis mediated 
by caspase 3/7 activation [58]. Radiation enhances G2/M 
arrest and apoptosis [59], so the combination of radiation 
and siPlk1 may delay tumor formation [60]. 
Hence, the underexpression of miR-100 will lead to the 
overexpression of Plk1, which in turn contributes to NPC 
development. So targeting of Plk1 to inhibit its overexpres-
sion will promote mitotic catastrophe and cell cycle arrest. 
This strategy has the potential to become an extremely 
powerful therapeutic approach when combined with effec-
tive ionizing radiation [61,62]. 
3.2  miRNA and tumor angiogenesis, invasion and mi-
gration 
Angiogenesis is fundamental for a wide variety of physio-
logical and pathological processes, including development, 
wound healing, inflammation and tumor formation [63]. 
Many small molecules play a positive role in the regulation 
of angiogenesis. Among them, vascular endothelial growth 
factor (VEGF) is the most important and its expression is 
under the control of multiple factors [64]. Hua et al. [65] 
determined that miR-16, miR-20a, miR-20b, let-7b, 
miR-17-5p, miR-27a, miR-106a, miR-106b, miR-107, 
miR-193a, miR-210, miR-320, miR-361 and miR-15b are 
predicted to target VEGF, and they may all modulate the 
expression of VEGF. 
Olsson et al. [66] demonstrated that under hypoxia 
stimulation, VEGF and other angiogenic factors are 
upregulated; these factors work together to induce angio-
genesis; under strict spatio-temporal conditions, miRNAs 
and various target genes can co-regulate multiple function-
ally related genes and angiogenic factors. Hua et al. [65] 
further showed that miR-15b, miR-16, miR-20a and 
miR-20b all have an effect on angiogenic factors in NPC 
cells; at the same time, there are seven angiogenesis related 
genes, VEGF, c-MET, COX2, uPAR, PAI1, MAPK7 and 
Ang that are all upregulated in NPC cells. 
Li et al. [67] reported that LMP1, which acts as a key 
regulator in promoting NPC metastasis [68], may induce the 
expression of transcription factor Twist, which in turn 
upregulates the expression of miR-10b to contribute to the 
metastasis of NPC. Meanwhile, by activating various signal 
transduction pathways, LMP1 can regulate the expression 
levels of multiple metastasis related genes, such as 
E-cadherin, MMPs, c-Met, VEGF, EGFR and COX-2 [69]. 
Sikumar et al. [70] suggested that the under-expression 
of miR-29c in NPC will lead to the upregulation of down-
stream target genes, which encode multiple extracellular 
matrix proteins, including collagens and laminin γ1 that are 
associated with invasion and migration of NPC cells. 
Hence, the downregulation of miR-29c in NPC cells con-
tributes to the invasive and metastatic characteristics of this 
cancer. Xia et al. [71] determined that miR-200a is down-
regulated and mediates the downregulation of the target 
genes, ZEB2 and CTNNB1, which inhibit cell growth, mi-
gration and metastasis in NPC. 
These studies suggest that different kinds of miRNA and 
their target genes are closely related to angiogenesis, inva-
sion and migration of NPC cells [72]. The interactions of 
miRNA and target genes could contribute to the metastasis 
of NPC. How can we modulate the expression of metasta-
sis-related miRNAs? And how can we block the biological 
functions of target genes? Answers to these questions re-
quire further research.  
4  Multiple NPC-related miRNAs and future 
research 
From the studies described above, we list the relationships 
between miRNA and NPC (Table 1) and summarize the 
recent discoveries related to NPC and miRNAs. 
From Table 1, we can see that there is great interest in 
studying the relationships between miRNA and the car-
cinogenesis of NPC. The fields of study range from 
EBV-encoded miRNAs, which affect host biological func-
tions, to the host cell’s self-encoded miRNAs, which play a 
crucial role in the development of NPC. Furthermore, we 
recommend that additional studies of miRNA are justified 
to answer questions such as: Do miRNAs exist in NPC that 
can enter the nucleus and function as transcription factors? 
Is there an RNA binding protein, similar to Dnd1 (Dead end 
1), that could bind to the adjacent genomic regions where 
miRNAs and target genes interact with each other? Can 
such an RNA binding protein indirectly inhibit the interac-
tions between miRNA and target genes? In NPC diagnosis 
and treatment, does a highly specific miRNA exist that can 
be detected in serum or body fluid of NPC patients? Can 
this miRNA act as a biomarker for the early diagnosis of 
NPC? In addition, for chemotherapy or radiation therapy, do 
miRNAs exist whose expression would enhance the sensi-
tivity of treatment? These problems are critical issues that 
need to be addressed in future work.  
Recent progress in understanding NPC carcinogenesis has 
shown that miRNAs are involved in LMP1 signaling. Future 
work should, therefore, focus on exploring the interactions 
between miRNAs and kinases, transcription factors and target 
genes in the signal transduction pathways activated by LMP1. 
We should also pay more attention to the metastasis-related 
genes. LMP1 can modulate the expression of miRNAs that 
then regulate the expression of metastasis-related genes; 
therefore, addressing these areas will help produce a better 
understanding of the role of miRNA in the invasion and  
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Table 1  NPC-related miRNAa) 
miRNA Target Biological functions Expression level of miRNA in NPC References 
ebv-miR-BART 
cluster 1 LMP1 
Invasion, metastasis, immortalization,  
apoptosis, proliferation ↑ [37] 
ebv-miR-BART 6 Dicer EBV infection and latency ↑ [31] 
ebv-miR-BART 5 PUMA Inhibit cell apoptosis ↑ [30] 
ebv-miR-BHRF1-3 CXCL11 Immune protection ↑ [29] 
miR-141 BRD3, UBAP1, PTEN 
Affect cell cycle, apoptosis, growth,  
migration, invasion ↑ [44] 
miR-29c Extracellular matrix  proteins Invasion, metastasis ↓ [70] 
miR-200a ZEB2, CTNNB1 Cell growth, migration, metastasis ↓ [71] 
miR-15b, miR-16, 






Involve in the regulation of signaling 
 pathway, cell cycle, apoptosis,  
cytoskeletal remodeling 
↓ [40] 
miR-100 Plk1 Affect mitosis and cell cycle ↓ [55] 
miR-155 PU.1 Induce cell growth, differatiation, apoptosis, involve in activation of lymphocyte ↑ [36] 
miR-10b Unidentified Invasion, metastasis ↑ [67] 
a) ↑ and ↓ indicate that the expression level of miRNA are up-regulated and down-regulated in NPC, respectively. 
 
metastasis of NPC, and will also provide new targets for the 
treatment of metastasis and recurrence of NPC. 
Plk1 is another target that warrants attention. Plk1 has an 
important role in the regulation of the cell cycle and mitosis 
in NPC, at the same time, interacts with the effects of radia-
tion therapy. Therefore, further research on the interaction 
between Plk1 related miRNAs and radiation will bring new 
hope for the treatment of NPC. 
In conclusion, we believe that further research on the re-
lationships between miRNA and NPC carcinogenesis will 
not only provide new understanding of the development of 
NPC, but also provide new avenues for the diagnosis and 
treatment of NPC. 
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